Jerzy Gumulka - Feb 1, 2024 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role
Director
Signature
/s/ Christopher Downs, Attorney-in-Fact
Stock symbol
CNSP
Transactions as of
Feb 1, 2024
Transactions value $
$10,000
Form type
4
Date filed
2/6/2024, 10:28 AM
Previous filing
Oct 12, 2023
Next filing
Apr 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNSP Common stock Purchase $10K +33.3K +344.6% $0.30 43K Feb 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNSP Series A Warrant to purchase common stock Award +33.3K +73.38% 78.8K Feb 1, 2024 Common Stock 33.3K $0.30 Direct F1
transaction CNSP Series B Warrant to purchase common stock Award +33.3K +42.32% 112K Feb 1, 2024 Common Stock 33.3K $0.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.